Clinical Value of Lipoprotein Testing for CHD and Stroke Risk Assessment
A fasting lipoprotein profile (total cholesterol, triglycerides, HDL-C, and LDL-C) should be obtained every 5 years in all adults to assess cardiovascular risk, with more frequent testing if ≥2 CHD risk factors are present or if LDL-C levels are borderline or high. 1
Core Lipoprotein Panel Components and Their Value
The standard lipid panel provides essential risk stratification for both coronary heart disease and stroke:
Primary Risk Markers
LDL-cholesterol remains the primary therapeutic target for both CHD and stroke prevention, with treatment goals stratified by overall cardiovascular risk 1. The evidence demonstrates:
- LDL-C is significantly predictive of future CHD events across all studies 2
- For stroke, LDL-C shows weaker associations than for CHD, though the trend is similar 2, 3
- Total cholesterol and non-HDL-C (calculated as total cholesterol minus HDL-C) are also significant predictors, with non-HDL-C particularly useful when triglycerides are >200 mg/dL 1
HDL-cholesterol provides independent risk information, with low HDL-C (<40 mg/dL) indicating increased risk 1. The data show HDL-C is inversely associated with CHD events, though its relationship with stroke is less robust 2, 4.
Triglycerides and Non-HDL-C
When triglycerides exceed 200 mg/dL, non-HDL-C becomes the secondary treatment target, with goals set 30 mg/dL higher than LDL-C goals 1. This captures the atherogenic potential of triglyceride-rich remnant particles.
Lipoprotein(a) Testing: Selective Rather Than Universal
Screening for Lp(a) is NOT recommended for routine primary prevention 1. However, Lp(a) testing is reasonable in specific high-risk scenarios:
- Unexplained early cardiovascular events in first-degree relatives
- Known high Lp(a) in first-degree relatives
- Premature CVD or recurrent events despite optimal lipid-lowering therapy 5
The rationale: Lp(a) is genetically determined and elevated in approximately 20% of individuals (>50 mg/dL or >125 nmol/L) 5, 6. While elevated Lp(a) increases risk for both MI and stroke 7, 8, 9, there is no consensus treatment goal, and therapeutic options are limited to niacin (up to 2000 mg/day) with modest Lp(a)-lowering effects 1.
Recent data show that among young ischemic stroke patients (age ≤60), only 4.9% underwent Lp(a) testing from 2015-2024, despite its causal role 6. This represents a significant implementation gap, though testing rates are increasing.
Comparative Strength: CHD vs Stroke Prediction
Critical distinction: The predictive value of lipid markers differs substantially between CHD and stroke:
- Lipid levels are stronger predictors of CHD than ischemic stroke 2, 3
- In the PRIME Study of 9,711 men, all lipid markers significantly predicted CHD, but none reached statistical significance for ischemic stroke, though trends were similar 2
- The magnitude of effect for stroke is consistently smaller than for CHD across all lipid parameters 3
Interestingly, hs-CRP associates more closely with ischemic stroke than with CHD (HR 2.76 for stroke vs 1.66 for CHD), suggesting inflammation may play a relatively larger role in stroke pathogenesis 3.
Practical Testing Recommendations
Screening Frequency
- Every 5 years for average-risk adults 1
- More frequently if:
- ≥2 CHD risk factors present (smoking, hypertension, HDL-C <40 mg/dL, family history of premature CHD, age >45 years for men or >55 years for women)
- LDL-C levels are borderline or high
- Diabetes or CHD risk equivalents present (peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid artery disease) 1
Fasting vs Non-Fasting
Non-fasting lipid screening is acceptable for initial assessment 10. However, obtain fasting lipids when:
- Initial screening shows abnormalities
- Triglycerides need accurate measurement
- Precise LDL-C calculation is required 10
Advanced Testing Considerations
Apolipoprotein B (ApoB) and LDL particle number (LDL-P) may help guide decisions in select patients, but data are limited for those already on lipid-lowering therapy with low LDL-C levels 10. The 2019 ACC/AHA guidelines note that the contribution of ApoB to cardiovascular risk assessment remains uncertain 11, 12.
Common Pitfalls to Avoid
- Don't assume equal predictive value: Lipids predict CHD more strongly than stroke—adjust clinical interpretation accordingly
- Don't routinely test Lp(a) in average-risk primary prevention—reserve for specific high-risk scenarios
- Don't use Friedewald formula when triglycerides >400 mg/dL—LDL-C estimation becomes unreliable; consider direct measurement or Martin/Hopkins method for TG 150-399 mg/dL 10
- Don't ignore non-HDL-C when triglycerides are elevated—it becomes the more reliable target 1